AKR1A1

AKR1A1 Full Name

aldo-keto reductase family 1, member A1 (aldehyde reductase)

AKR1A1 Introduction

AKR1A1, also known as aldehyde reductase or alcohol dehydrogenase, is a member of the aldo-keto reductase superfamily that catalyzes the NADPH-dependent reduction of a wide range of aldehydes and ketones to their corresponding alcohols. The human AKR1A1 gene is located on chromosome 1p33-p32, spans a moderate genomic region, and contains several exons encoding a protein of approximately thirty-five kilodaltons. AKR1A1 is ubiquitously expressed in all human tissues, with the highest levels detected in the liver, kidney, brain, and red blood cells, reflecting its essential role in detoxification and metabolism. The enzyme belongs to the AKR1A subfamily, which includes aldose reductase and other related enzymes, but AKR1A1 is distinguished by its broad substrate specificity and its preference for aldehyde substrates over sugar aldehydes. Within the cell, AKR1A1 is primarily cytosolic, though a fraction has also been reported in the nucleus and mitochondria in certain cell types. The enzyme adopts a typical aldo-keto reductase fold consisting of a beta-alpha-beta barrel structure with a conserved catalytic tetrad that positions the NADPH cofactor for hydride transfer. Through its ability to reduce toxic aldehydes derived from lipid peroxidation, drug metabolism, and endogenous metabolic pathways, AKR1A1 serves as a critical detoxification enzyme that protects cells from oxidative stress and carbonyl toxicity. Additionally, AKR1A1 contributes to the metabolism of various drugs, xenobiotics, and endogenous signaling molecules, and its dysregulation has been implicated in drug resistance, neurodegeneration, and cancer.

Figure 1. Schematic structure of AKR1A1.

Enzymatic Properties and Catalytic Mechanism
AKR1A1 catalyzes the NADPH-dependent reduction of aldehydes to primary alcohols and, to a lesser extent, the reduction of ketones to secondary alcohols. The enzyme exhibits remarkably broad substrate specificity, accepting a wide range of aliphatic, aromatic, and medium-chain aldehydes as substrates. The most efficiently reduced substrates are medium-chain aldehydes, such as hexanal, heptanal, and octanal, which are products of lipid peroxidation. AKR1A1 also efficiently reduces the toxic aldehyde methylglyoxal, a byproduct of glycolysis, to acetol, and reduces the neurotransmitter-derived aldehyde 3,4-dihydroxyphenylacetaldehyde to the corresponding alcohol. The enzyme has lower but still significant activity toward the lipid peroxidation product 4-hydroxynonenal, a highly reactive aldehyde that forms protein adducts and causes cellular damage. The catalytic mechanism follows an ordered sequential pathway in which NADPH binds first, followed by the aldehyde substrate. The aldehyde carbonyl carbon is positioned near the nicotinamide ring of NADPH, and a hydride ion is transferred from NADPH to the aldehyde carbon. A conserved tyrosine residue acts as a proton donor, transferring a proton to the carbonyl oxygen and generating the alcohol product. The product alcohol is then released, followed by NADP, and the enzyme is recycled by reduction of NADP to NADPH via the pentose phosphate pathway or other NADPH-generating systems. The enzyme has a pH optimum near neutral and is inhibited by certain flavonoids and by the antidepressant drug sertraline, which compete with NADPH binding.

Role in the Nervous System and Neurodegenerative Diseases
AKR1A1 is expressed in neurons throughout the brain, where it protects against aldehyde-induced neurotoxicity. The brain is particularly vulnerable to oxidative stress due to its high oxygen consumption, high polyunsaturated fatty acid content, and relatively low antioxidant capacity. Lipid peroxidation in the brain generates reactive aldehydes that have been implicated in the pathogenesis of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. AKR1A1 reduces these aldehydes to less toxic alcohols, thereby protecting neurons from damage. In postmortem brain tissue from patients with Alzheimer's disease, AKR1A1 expression is reduced in the hippocampus and cerebral cortex compared to age-matched controls, and the remaining enzyme shows altered activity and localization. Similarly, in animal models of Parkinson's disease induced by the neurotoxin MPTP, AKR1A1 expression is upregulated in surviving neurons, possibly as a protective response. Genetic variants in the AKR1A1 gene have been associated with risk for sporadic Parkinson's disease in some populations, though the effect is modest and the functional variant has not been identified.

Alternate Names for AKR1A1

AKR1A1; aldo-keto reductase family 1, member A1 (aldehyde reductase); alcohol dehydrogenase [NADP(+)]; ALR; DD3; dihydrodiol dehydrogenase 3; aldehyde reductase; alcohol dehydrogenase; aldo-keto reductase family 1 member A1; ARM; ALDR1; MGC1380; MGC12529;

View more